Project Grant R01CA317668
Award Date 6/22/26
Completion Date 5/31/31
Dollars Obligated $696K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a $683,256 Project Grant under the Cancer Biology Research program (CFDA 93.396) on May 22, 2026, with a completion date of April 30, 2031. This award funds a human-mouse platform initiative designed to advance patient stratification, target discovery, and validation in glioblastoma (GBM) treatment. The project addresses the critical challenge of tumor heterogeneity by integrating...
- Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a $628,394 Project Grant under the Cancer Biology Research program (CFDA 93.396) on May 8, 2026, with a completion date of April 30, 2031. The project delivers research and development services focused on organoid-immune cell culture modeling to advance therapeutic response prediction in intrahepatic cholangiocarcinoma (ICCA). The awardee has developed a patient-derived organoid with tumor...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a $697,131 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, through April 30, 2031. This fundamental research initiative addresses immune resistance mechanisms in colorectal cancer (CRC) by investigating the myeloid-stromal axis in the tumor microenvironment. The research will deliver scientific findings on how cancer-associated...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a Project Grant totaling $714,317 under the Cancer Biology Research program (CFDA 93.396) to support fundamental research on prostate cancer progression and therapeutic resistance. The five-year award, effective August 1, 2025 through July 31, 2030, funds research investigating the molecular mechanisms linking epithelial-mesenchymal transition (EMT), mesenchymal-epithelial transition...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a $2.69 million Project Grant under the Cancer Biology Research program (CFDA 93.396) on September 24, 2025, with completion scheduled for August 31, 2029. This award supports fundamental research investigating the mechanisms and impact of Neuregulin 3 (NRG3) induction in bone metastasis of breast cancer. The project will employ molecular and genetic approaches to...
- Federal Grant Award Summary The National Cancer Institute awarded a $671,252 Project Grant to Sloan-Kettering Institute For Cancer Research under the Cancer Biology Research program (CFDA 93.396) to investigate the mechanisms of anti-tumor immunity mediated by immune cell triads. The research project, effective from July 1, 2026 through June 30, 2031, will advance fundamental understanding of how CD4 T cells, CD8 T cells, and dendritic cells must spatially organize and interact within tumors...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $147,083 to Icahn School of Medicine at Mount Sinai on August 1, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support biomedical research training and workforce development in cancer research. The grant, which extends through June 30, 2026, funds a postdoctoral research project titled "Deconstructing Pathogenic Myelopoiesis in Cancer Immunosuppression and Treatment Resistance." This...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a five-year Project Grant totaling $1,365,772 under the Cancer Biology Research program (CFDA 93.396) beginning May 1, 2026, with completion scheduled for April 30, 2031. This award funds fundamental cancer biology research focused on understanding the role of ATAD2 (AAA-ATPase Containing Domain Protein 2) in prostate cancer progression and bone metastasis. The research...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $169,000 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Icahn School of Medicine at Mount Sinai, effective August 1, 2025, through July 31, 2027. This research grant supports a two-year investigation into epigenetic regulation of melanoma-associated fibroblast plasticity, specifically examining how histone variant dysfunction affects the tumor microenvironment (TME). The principal...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...